Advanced colorectal cancer (CRC) patients with a RAS/RAF wild-type status obtain significant benefits from anti-epidermal growth factor receptor antibody (anti-EGFR) therapy in combination with chemotherapy (1–5). The gene discussed is EGFR; the disease is colorectal carcinoma.